Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian (Africa)
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian (Africa)
Keir Starmer often strident in opposition struggles to maintain probity in government
30/10/2025
Prince Andrew to be stripped of titles and move out of Royal Lodge
30/10/2025
Borthwick hopes England can emulate Bazball mentality for autumn series
30/10/2025
Apple to report earnings as new iPhone lineup reignites worldwide demand
30/10/2025
‘You got some pants on, officer ?’ : video from Detroit virtual court hearing goes viral
30/10/2025
US Senate votes to end Trump’s global tariffs on more than 100 countries
30/10/2025